文献速递胃肠动力与功能性疾病

低FODMAP饮食可减轻肠易激综合征患者症状且益生菌可恢复双歧杆菌属:一项随机对照试验

A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2017-06-15

该随机对照试验纳入104例肠易激综合征患者,采用2×2析因设计比较低FODMAP饮食与假饮食、多菌株益生菌与安慰剂。低FODMAP饮食组症状缓解率在符合方案分析中显著高于假饮食组,症状严重度评分显著降低,但双歧杆菌属丰度降低;益生菌可提高双歧杆菌属丰度。

要点

  • 低FODMAP饮食组在符合方案分析中症状充分缓解率显著高于假饮食组(61% vs 39%,P=.042)。
  • 低FODMAP饮食组IBS严重度评分显著低于假饮食组(173±95 vs 224±89,P=.001)。
  • 益生菌组双歧杆菌属丰度显著高于安慰剂组(9.1 vs 8.8 rRNA基因/g,P=.019)。

核心结论

  • 在安慰剂对照研究中,低FODMAP饮食与肠易激综合征患者症状充分缓解相关,且症状评分较假饮食显著降低。
  • 尚不清楚症状改善是源于FODMAP总体限制还是去除了单一成分(如乳糖)。
  • 同时给予多菌株益生菌可增加双歧杆菌属数量,或可用于恢复低FODMAP饮食患者的双歧杆菌。

研究设计与样本

  • 研究为2×2析因随机对照试验,纳入104例符合罗马III标准的肠易激综合征患者(18-65岁),来自英国2家医院。
  • 患者随机分配接受假饮食或低FODMAP饮食咨询4周,同时给予安慰剂或多菌株益生菌制剂,共4组:假饮食/安慰剂27例、假饮食/益生菌26例、低FODMAP饮食/安慰剂24例、低FODMAP饮食/益生菌27例。
  • 共同主要终点为4周时症状充分缓解和粪便双歧杆菌属丰度。

主要发现

  • 两种干预对症状充分缓解(P=.52)或双歧杆菌属(P=.68)无显著交互作用。
  • 意向治疗分析中,低FODMAP饮食组症状充分缓解比例(57%)高于假饮食组(38%),但差异未达统计学显著(P=.051)。
  • 符合方案分析中,低FODMAP饮食组症状充分缓解比例(61%)显著高于假饮食组(39%)(P=.042)。
  • 低FODMAP饮食组IBS严重度评分总分均值(173±95)显著低于假饮食组(224±89)(P=.001);益生菌组(207±98)与安慰剂组(192±93)无显著差异(P=.721)。
  • 低FODMAP饮食组粪便双歧杆菌属丰度(8.8 rRNA基因/g)低于假饮食组(9.2 rRNA基因/g)(P=.008);益生菌组(9.1 rRNA基因/g)高于安慰剂组(8.8 rRNA基因/g)(P=.019)。

关键数值与推荐

  • 低FODMAP饮食组符合方案分析症状充分缓解率61%,假饮食组39%(P=.042)。
  • 低FODMAP饮食组IBS严重度评分总分均值173±95,假饮食组224±89(P=.001)。
  • 低FODMAP饮食组双歧杆菌属丰度8.8 rRNA基因/g,假饮食组9.2 rRNA基因/g(P=.008)。
  • 益生菌组双歧杆菌属丰度9.1 rRNA基因/g,安慰剂组8.8 rRNA基因/g(P=.019)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出尚不清楚症状改善是源于FODMAP总体限制还是去除了单一成分(如乳糖)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS. METHODS: We performed a 2×2 factorial trial of 104 patients with IBS (18-65 years old), based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly assigned (blinded) to groups given counselling to follow a sham diet or diet low in FODMAPs for 4 weeks, along with a placebo or multistrain probiotic formulation, resulting in 4 groups (27 receiving sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP diet /placebo, and 27 receiving low FODMAP diet/probiotic). The sham diet restricted a similar number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease-specific health-related quality of life, using standard scoring systems. All data were collected again at 4 weeks, and patients answered questions about adequate symptom relief. Fecal samples were collected at baseline and after 4 weeks and analyzed by quantitative PCR and 16S rRNA sequencing. The co-primary endpoints were adequate relief of symptoms and stool Bifidobacterium species abundance at 4 weeks. RESULTS: There was no significant interaction between the interventions in adequate relief of symptoms (P = .52) or Bifidobacterium species (P = .68). In the intention-to-treat analysis, a higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) than in the sham diet group (38%), although the difference was not statistically significant (P = .051). In the per-protocol analysis, a significantly higher proportion of patients on the low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) (P = .042). Total mean IBS-Severity Scoring System score was significantly lower for patients on the low FODMAP diet (173 ± 95) than the sham diet (224 ± 89) (P = .001), but not different between those given probiotic (207 ± 98) or placebo (192 ± 93) (P = .721) Abundance of Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet (8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P = .008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) (P = .019). There was no effect of the low FODMAP diet on microbiota diversity in fecal samples. CONCLUSIONS: In a placebo-controlled study of patients with IBS, a low FODMAP diet associates with adequate symptom relief and significantly reduced symptom scores compared with placebo. It is not clear whether changes resulted from collective FODMAP restriction or removal of a single component, such as lactose. Co-administration of the multistrain probiotic increased numbers of Bifidobacterium species, compared with placebo, and might be given to restore these bacteria to patients on a low FODMAP diet. Trial registration no: ISRCTN02275221.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Staudacher HM, Lomer MCE, Farquharson FM, et al. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017. PMID: 28625832. doi:10.1053/j.gastro.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。